Mesoblast (Nasdaq:MESO; ASX:MSB), global leader in allogeneic cellular medicines for inflammatory diseases, today announced alignment with the United States Food and Drug Administration (FDA) on items ...

Mesoblast Limited (NASDAQ:MESO) is one of the 7 Best ASX Stocks to Buy Now. The company announced that it received 7 years of orphan-drug exclusive approval from the US FDA for Ryoncil® (remestemcel-L ...

During a live event, Nelson J. Chao, MD, discussed key outcomes from the trials supporting the use of ruxolitinib and ...

The 7MM Graft Versus Host Disease (GvHD) market has demonstrated substantial growth in recent years, fueled by rising transplant rates, an aging population, and the introduction of innovative ...

Graft-versus-host disease (GVHD) is a potentially serious complication of a bone marrow transplant, but it can be successfully treated and managed.

Skin, gastrointestinal, and liver symptoms are common manifestations of graft-versus-host disease (GVHD). The potentially life threatening complication is from allogeneic hematopoietic stem cell ...

Control of graft-versus-host disease (GVHD) is critical for the success of allogeneic hematopoietic stem-cell transplantation (HSCT). Nearly 40 years ago, the combination of methotrexate and a ...

Chronic graft-versus-host disease (cGVHD) occurs in 30%-60% of patients with leukemia who receive unmanipulated donor HLA-matched peripheral blood stem-cell (PBSC) allografts and is a major source of ...

A recent report published in Science Translational Medicine by MUSC Hollings Cancer Center investigator Sophie Paczesny, M.D., Ph.D., sheds light on immune cell biomarkers that may reveal which ...

When T cells from a bone marrow donor begin to attack the host within 3 months after hematopoietic-cell transplantation, acute graft-versus-host disease results. The disease mainly affects the skin ...

Acute graft-versus-host disease (GVHD) of the gastrointestinal tract is a common complication in patients after haematopoietic stem cell transplantation (HSCT) that results in considerable ...